(Q34276090)

1 August 2017

title

Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection (English)

1 reference

1 August 2017

main subject

Clostridium difficile

0 references

antibiotic

0 references

fidaxomicin

1 reference

ChEBI release 2020-05-28

Tonya Crawford

1

1 reference

1 August 2017

Emily Huesgen

series ordinal

2

1 reference

1 August 2017

Larry Danziger

series ordinal

3

1 reference

1 August 2017

publication date

1 June 2012

1 reference

American Journal of Health-System Pharmacy

1 August 2017

published in

1 reference

1 August 2017

volume

69

1 reference

1 August 2017

issue

11

1 reference

1 August 2017

page(s)

933-943

1 reference

Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile Infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

The changing epidemiology of Clostridium difficile infections

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

An epidemic, toxin gene-variant strain of Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clostridium difficile toxins: mechanism of action and role in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clostridium difficile and the disease it causes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clostridium difficile--more difficult than ever

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clostridium difficile: controversies and approaches to management.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Alternative treatments for Clostridium difficile disease: what really works?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, bilogical and biochemical characterization.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Tiacumicins, a novel complex of 18-membered macrolide antibiotics. I. Taxonomy, fermentation and antibacterial activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

In vitro activity of OPT-80 against Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

In vitro activities of OPT-80 and comparator drugs against intestinal bacteria

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Effects of inoculum, pH, and cations on the in vitro activity of fidaxomicin (OPT-80, PAR-101) against Clostridium difficile

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Fidaxomicin versus vancomycin for Clostridium difficile infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP110371

31 March 2020

Identifiers

DOI

10.2146/AJHP110371

1 reference

1 August 2017

1 reference